May. 13 at 8:42 PM
$CLPT
🚨🚨🚨
ClearPoint Neuro reported first-quarter 2026 revenue of
$12.1 million, up 43% from
$8.5 million a year earlier, driven by IRRAflow contributions and strong device demand.
Organic revenue grew 16%, with organic devices up 25%, and gross margin improved to 64% from 60%.
Neurosurgery navigation, therapy and access revenue rose 80% to
$5.9 million, while capital equipment and software revenue climbed 177% to
$1.4 million.
Operating expenses increased 44% to
$16.2 million, reflecting the IRRAS acquisition and higher personnel and occupancy costs, resulting in a net loss of
$9.6 million (–
$0.32 per share).
The company ended March 31, 2026 with
$35.6 million in cash and cash equivalents, down from
$45.9 million at year-end.
ClearPoint issued a 2026 revenue outlook of
$52.0–
$56.0 million and highlighted integration of the IRRAflow portfolio, more than 60 active biopharma partners
